Beijing Science Sun Pharmaceutical (300485) Fundamentals 2026 — Revenue Analysis | SniperIQ
Beijing Science Sun Pharmaceutical (300485) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥4.3B, trading at ¥9.00 on the SHZ. This SniperIQ fundamentals page covers Beijing Science Sun Pharmaceutical's valuation, profitability (net margin -5.2%), revenue (¥405M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Beijing Science Sun Pharmaceutical's market cap?
Beijing Science Sun Pharmaceutical (300485) has a market capitalization of approximately ¥4.3B, trading at ¥9.00 on the SHZ. Market cap moves with the live share price.
What is Beijing Science Sun Pharmaceutical's P/E ratio?
Beijing Science Sun Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Beijing Science Sun Pharmaceutical?
Beijing Science Sun Pharmaceutical runs a net profit margin of -5.2%, a gross margin of 66.5%, and an operating margin of -6.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Beijing Science Sun Pharmaceutical generate?
Beijing Science Sun Pharmaceutical reported revenue of ¥405M for fiscal year 2025, with net income of ¥15M and earnings per share (EPS) of 0.03. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Beijing Science Sun Pharmaceutical pay a dividend?
Beijing Science Sun Pharmaceutical offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Beijing Science Sun Pharmaceutical financially healthy?
Beijing Science Sun Pharmaceutical carries a debt-to-equity ratio of 0.01x and a current ratio of 20.09x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Beijing Science Sun Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beijing Science Sun Pharmaceutical (300485) the key facts are: market cap ¥4.3B, revenue ¥405M, 52-week range 7.77-16.76. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Beijing Science Sun Pharmaceutical's full fundamentals live
Get Beijing Science Sun Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.